Prognostic Value of Liver Kinase B1 (LKB1) in Gastric Cancer-Associated Tumor Microenvironment Immunity

Chen, Yongyi; Chen, Siyu; Zhu, Jing; Liu, Xin; Gong, Wangang; Zhou, Sihang; Xu, Songxiao

doi:10.3390/biomedicines11030688

Open AccessArticle

Prognostic Value of Liver Kinase B1 (LKB1) in Gastric Cancer-Associated Tumor Microenvironment Immunity

by

Yongyi Chen

^1,2,

Siyu Chen

^1,2,

Jing Zhu

^1,2,

Xin Liu

^1,2,

Wangang Gong

^1,2,

Sihang Zhou

^1,2 and

Songxiao Xu

^1,2,*

¹

The Clinical Laboratory Department, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou 310022, China

²

The Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310022, China

^*

Author to whom correspondence should be addressed.

Biomedicines 2023, 11(3), 688; https://doi.org/10.3390/biomedicines11030688

Submission received: 19 January 2023 / Revised: 15 February 2023 / Accepted: 19 February 2023 / Published: 23 February 2023

(This article belongs to the Section Cancer Biology and Oncology)

Download

Browse Figures

Versions Notes

Abstract

Liver kinase B1 (LKB1) is a tumor suppressor gene, the inactivation of which occurs frequently in different tumor types. However, whether LKB1 is associated with the clinical features of gastric cancer (GC) and regulating tumor immunity is unknown. In this study, we showed that LKB1 is highly expressed in the serum of healthy individuals (n = 176) compared to GC patients (n = 416) and is also associated with clinical outcomes and good survival rates in GC patients. Furthermore, genes associated with immune checkpoints and T cell activation, such as PD−1, PD−L1, CD8A, CD8B, CD28, and GZMM, were shown to be highly expressed in GC subgroups with high LKB1 expression. Compared with fresh gastric cancerous tissues, LKB1 was highly expressed in CD3+CD8+ and CD3+CD8+CD28+ T cells in fresh adjacent non-cancerous tissues. CD3+CD8+ T cells produced an IFN−γ anti−cancer immune response. Furthermore, the proportion of CD3+CD8+ T cells that expressed LKB had a positive correlation with IFN−γ expression. Moreover, GC patients with low LKB1 expression had a poor objective response rate, and worse progression-free survival and overall survival when treated with pembrolizumab. In conclusion, LKB1 may be a potential immune checkpoint in GC patients.

Keywords: LKB1; gastric cancer; clinical outcomes; immune checkpoint; CD3+CD8+ T cells

Share and Cite

MDPI and ACS Style

Chen, Y.; Chen, S.; Zhu, J.; Liu, X.; Gong, W.; Zhou, S.; Xu, S. Prognostic Value of Liver Kinase B1 (LKB1) in Gastric Cancer-Associated Tumor Microenvironment Immunity. Biomedicines 2023, 11, 688. https://doi.org/10.3390/biomedicines11030688

AMA Style

Chen Y, Chen S, Zhu J, Liu X, Gong W, Zhou S, Xu S. Prognostic Value of Liver Kinase B1 (LKB1) in Gastric Cancer-Associated Tumor Microenvironment Immunity. Biomedicines. 2023; 11(3):688. https://doi.org/10.3390/biomedicines11030688

Chicago/Turabian Style

Chen, Yongyi, Siyu Chen, Jing Zhu, Xin Liu, Wangang Gong, Sihang Zhou, and Songxiao Xu. 2023. "Prognostic Value of Liver Kinase B1 (LKB1) in Gastric Cancer-Associated Tumor Microenvironment Immunity" Biomedicines 11, no. 3: 688. https://doi.org/10.3390/biomedicines11030688

APA Style

Chen, Y., Chen, S., Zhu, J., Liu, X., Gong, W., Zhou, S., & Xu, S. (2023). Prognostic Value of Liver Kinase B1 (LKB1) in Gastric Cancer-Associated Tumor Microenvironment Immunity. Biomedicines, 11(3), 688. https://doi.org/10.3390/biomedicines11030688

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Prognostic Value of Liver Kinase B1 (LKB1) in Gastric Cancer-Associated Tumor Microenvironment Immunity

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI